Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. by Hall, R. E. et al.
British Journal of Cancer (1996) 74,1175-1180
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 f
Expression of the androgen receptor and an androgen-responsive protein,
apolipoprotein D, in human breast cancer
RE Hall 2, JO Aspinall', DJ Horsfall', SN Birrell', JM Bentell, RL Sutherland2 and WD Tilley'
'Cancer Cell Biology Unit, Department ofSurgery, School ofMedicine, Flinders University of South Australia, PO Box 2100,
Adelaide, SA 5001, Australia; 2Cancer Biology Division, Garvan Institute ofMedical Research, St Vincent's Hospital, Sydney, NSW
2010, Australia.
Summary Little is known regarding the activity and function of the androgen receptor (AR) in human breast
cancer. In the present study AR was evaluated in untreated primary breast cancers using antisera to the amino-
and carboxy-termini of the receptor and quantitated using colour video image analysis. A strong correlation
between tissue concentration and percentage AR-positive cells was observed for each antiserum. However,
comparison of percentage positive cells using the amino- and carboxy-terminal AR antisera in individual breast
cancer specimens revealed a subset of tumours with discordantly increased staining for the carboxy terminus.
These findings suggest the presence of amino-terminal-truncated AR in a proportion of breast cancer cells or
presence of AR mutations or associated protein alterations that affect binding of the amino-terminal AR
antiserum. Immunohistochemical expression of the androgen-regulated glycoprotein, apolipoprotein D (apo-
D), was also evaluated in the breast cancer specimens. Focal positivity of apo-D staining, which did not always
co-localise with AR-positive cells, was observed within breast tumours. Furthermore, no correlation was
evident between percentage positive cells stained for AR and apo-D in breast cancer specimens. These findings
indicate that, although apo-D expression is androgen regulated in human breast cancer cell lines in vitro, its
expression in primary breast cancers may be regulated by other factors. The expression of AR in primary
breast cancers also suggests that the receptor may be involved in tumour responsiveness or in abnormal
responses to endocrine therapies.
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Androgens regulate breast cancer cell proliferation in vitro via
interaction with the androgen receptor (AR) (Truss and
Beato, 1993). However, divergent responses to androgens are
seen in different human breast cancer cell lines. For example,
androgens may stimulate (MCF-7, EFM-19, EVSA-T, MDA-
MB-453) or inhibit (T-47D, ZR-75-1, MFM-223) the growth
of AR-positive breast cancer cell lines in vitro (Birrell et al.,
1995a; Hackenberg et al., 1988, 1991; Hall et al., 1994;
Marugo et al., 1992; Poulin et al., 1988). This divergent
proliferative response to androgens may in part be due to
alterations in the AR gene, resulting in altered receptor
function and activation of androgen-regulated genes (Berger
and Watson, 1989), or interaction between AR and other
steroid receptors [e.g. oestrogen receptor (ER) and progester-
one receptor (PR)] differentially expressed in breast cancer
cells.
Sensitive immunostaining techniques indicate that up to
80% of human breast tumours are AR-positive (Isola, 1993;
Kuenen-Boumeester et al., 1992) and, perhaps more
importantly, 25% of breast tumour metastases express AR
when ER and PR levels are undetectable (Lea et al., 1989).
Although androgens are not routinely used in the treatment
of human breast cancer owing to the unacceptable side-effects
of treatment, indirect clinical evidence suggests that the AR
may be an important mediator of hormonal therapy in breast
tumours in vivo (Bryan et al., 1984). We recently reported
that the level of AR expression in primary breast cancers was
the sole predictor of response to medroxyprogesterone
acetate (MPA) administered following relapse on tamoxifen
therapy (Birrell et al., 1995b). MPA, a synthetic progestin
widely used in the treatment of metastatic breast cancer,
binds to the AR with high affinity (S Birrell and WD Tilley,
unpublished results). Thus, the clinical and in vitro findings
suggest that the. anti-tumour activity and/or androgenic side-
effects observed in women treated with MPA may be
mediated in part by the AR.
Previous studies in our laboratory using computerised
colour video image analysis (VIA) to compare prostate
cancers stained with antisera directed against the amino- and
carboxy-termini of the AR, identified a subgroup of tumours
with discordant staining between the two AR antisera (Tilley
et al., 1994). It was proposed that the differences in AR
staining observed with the two antisera might be due to
structural alterations in the receptor. This has subsequently
been confirmed by analysis of the AR gene sequence in the
same group of prostate cancer patients (Tilley et al., 1996). In
contrast, prostate specimens derived from patients with
benign disease exhibited concordant immunostaining with
the amino- and carboxy-terminal AR antisera and amino acid
substitutions in the AR were detected in only a single
specimen (Tilley et al., 1996). These studies demonstrate the
use of immunohistochemical techniques to examine the
structure of AR in tissue specimens.
AR function or mutations in the AR gene have not been
extensively investigated in human breast cancers. The
development of breast cancer in three men has been linked
to inherited mutations in the DNA-binding domain of the
AR (Lobaccaro et al., 1993; Wooster et al., 1992), while in a
recent report it was demonstrated that the human breast
cancer cell lines, MCF-7 and T-47D, contain a splice variant
of AR missing exon 3 (Zhu et al., 1996). If present in breast
tumours in vivo, AR variants may contribute to breast cancer
cell growth and responsiveness or resistance to hormonal
therapies.
Apolipoprotein D (apo-D), or gross cystic disease fluid
protein 24 (GCDFP-24), is a glycoprotein present in high
concentrations in human breast gross cystic disease fluid
(Balbin et al., 1990). Apo-D is also expressed in breast
cancers and the cellular levels of apo-D may be used to
predict disease-free interval and overall survival (Diez-Itza et
al., 1994). In vitro studies using human breast cancer cell lines
have demonstrated that apo-D expression is regulated by
androgens and glucocorticoids (Haagensen et al., 1992;
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Simard et al., 1992), retinoic acid (Lopez-Boado et al., 1994)
and the cytokine, interleukin la (Blais et al., 1994). The
promoter region of the apo-D gene contains response
elements for transforming growth factor # and the steroid
hormone receptors, ER, PR and glucocorticoid receptor
(Lambert et al., 1993). Although the biological function of
tissue apo-D is unknown, the androgen regulation of apo-D
and the high-affinity binding of progesterone and pregneno-
lone to apo-D (Lea et al., 1987), suggest that it may be
involved in tissue metabolism and/or processing of steroids.
In order to define AR structure and activity in breast
cancer better, primary breast tumours were stained using
amino- and carboxy-terminal AR antibodies and the staining
intensity and distribution evaluated using colour VIA. Our
findings demonstrate AR immunoreactivity in all breast
tumour samples evaluated and suggest the presence of
structurally altered AR in a proportion of cancer speci-
mens. While in vitro studies have shown androgen regulation
of apo-D, the expression of AR and apo-D do not appear to
be related in breast cancers in vivo.
Materials and methods
Breast tissues
At the time of surgical excision of the primary tumour, 36
breast cancer specimens were chosen at random from patients
treated at the Surgical Oncology Unit, Flinders Medical
Centre (Bedford Park, South Australia). Patient and tumour
details are listed in Table I. Tumour size and axillary lymph
node involvement were determined by the Pathology
Department at Flinders Medical Centre and histological
grade was determined using the Bloom and Richardson
classification (Bloom and Richardson, 1957). One specimen
was ductal carcinoma in situ, seven tumours (19%) were
grade I, i.e. well-differentiated carcinomas, 16 tumours (44%)
were grade II and 12 tumours (33%) were grade III, i.e.
poorly differentiated carcinomas. ER and PR content of the
tumours was routinely determined by radioligand binding
(Birrell et al., 1995b) and an additional portion of each
tumour specimen was embedded in Tissue-Tek OCT
compound (Miles Scientific, Naperville, IL, USA) and frozen
at -70°C until processed.
Immunohistochemistry
Sections (5,m) were cut from either frozen tissue or
archival paraffin blocks and placed on poly-L-lysine
(Sigma, St Louis, MO, USA)-coated slides. To retrieve AR
antigenicity, paraffin sections were boiled in 10 mm citrate
buffer (pH 6.5) in a microwave for 15 min (Loda et al.,
1994). Immunoperoxidase staining for AR was performed as
previously described (Husmann et al., 1990; Tilley et al.,
1994) using three affinity-purified rabbit anti-peptide
antibodies that recognise epitopes in the amino terminus
(amino acids 1-21, designated ARU402), the internal A
domain (amino acids 200-220, designated ARU407) and the
carboxy terminus (amino acids 898-917, designated ARR489)
of the human AR (Zoppi et al., 1993). The AR antisera
Table I Characteristics of patients (n = 36)
Characteristic Median Range
Age (years) 62 31-82
Tumour size (mm) 24 9-50
Involved lymph nodes (no.) 2 0-10
Node negative (%) 56
ER (fmol mg-l protein) 62 0-1044
< 10 fmol mg-' protein (%) 22
PR (fmol mg-1 protein) 163 0-1133
<10 fmol mg 1 protein (%) 39
were generously provided by Drs Carol M Wilson, Michael
J McPhaul and Jean D Wilson, (Department of Internal
Medicine, University of Texas Southwestern Medical Center,
Dallas, TX, USA). Immunoperoxidase staining for apo-D
was performed as described previously (Aspinall et al., 1995;
Mazoujian and Haagensen, 1990). The apo-D antiserum was
generously provided by Dr Darrow E Haagensen (Methodist
Hospital, Sacramento, CA, USA). Serial sections were
stained with haematoxylin and eosin (for histological
confirmation), ARUQ2, ARU407, ARR489, apo-D and normal
rabbit serum (negative control). Specimens previously known
to be AR and apo-D positive were included as positive
controls. Immunopositive staining was detected with the
chromogen 3'3'-diaminobenzidine tetrahydrochloride (DAB,
Sigma) and the sections were counterstained with weak Lillie
Mayer's haematoxylin.
Colour video image analysis
Frozen sections stained for AR and apo-D were examined
using an Olympus BH-2 microscope (X200) coupled to a
computer-assisted colour video image analyser (Video Pro 32;
Leading Edge, Adelaide, South Australia, and Leica
Australia Pty Ltd, Adelaide, South Australia). These
methods have been described previously (Tilley et al., 1994).
VIA measurements were confined to the epithelial component
of tumour tissue and on-screen editing of captured images
was used to eliminate stromal, fat and other cell types. VIA
measurements were made of the total area of tissue analysed
(both positively and negatively stained cells), the positively
stained area and the integrated optical density (IOD) of
positive staining, for at least ten fields per section. From
these measurements the following parameters of staining were
derived for each sample: (1) the percentage area of positively
stained cells (area DAB/total epithelial area x 100) and (2)
the mean concentration of antigen expressed over the total
population of cancer cells (mean integrated optical density,
MIOD =IOD/total epithelial area). Immunostaining of
tumour sections was reproducible, as assessed by VIA, with
coefficients of variation of less than 5% for the mean area of
positively stained cells and IOD.
Statistical analysis
Data are presented as the median value for each patient
characteristic. The curve fit of the data for ARU402, ARR489
and apo-D staining parameters was calculated with Cricket
Graph software (Computer Associates International, Islan-
dia, NY, USA). Staining parameters for each antigen were
analysed by linear regression analysis and the statistical
significance level was set at a critical value (P) of less than
0.05.
Results
AR and apo-D immunohistochemistry
Immunohistochemical staining for the human AR was
localised to the nucleus of epithelial cells in breast tumours
(Figure la and b). Staining within specimens was hetero-
geneous, with both positively and negatively stained cells
evident in tumour foci. Although all tumours contained cells
that were positively stained for AR, the proportion of
immunopositive cells varied from a few to >50% of cells
stained. Stromal cells in all specimens were AR negative.
Apo-D was evident as granular cytoplasmic immunor-
eactivity in breast tumour cells. Stromal cells were negative
for apo-D. In 3 of 31 evaluable samples <1% positive
immunostaining was observed. Where apo-D staining was
present, immunoreactivity was focal with areas of apo-D-
positive cells among negatively stained tumour cells (Figure
1c). In sequential sections stained for ARU402 and apo-D, it
was evident that ARU402 and apo-D were sometimes, but not
always, coexpressed in areas of the same tumour.Video image analysis of AR and apo-D immunohistochemistry
VIA of AR indicated that the mean percentage positive cells
stained with the amino-terminal antibody, ARUQ2, ranged
from 2% to 60% (median 27%). The mean percentage
positive cells stained with the carboxy-terminal antibody,
ARR489, ranged from 3% to 72% (median 49%). The
percentage of positively stained cells and mean concentration
of antigen (MIOD) in each specimen were significantly
related for both ARU402 (P=0.0001; Figure 2a) and ARR489
staining (P=0.0001; Figure 2b). These findings indicated that
as the proportion of positively stained cells in individual
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tumour specimens increased, the intensity of staining (i.e.
tissue AR concentration) also increased.
In order to evaluate the structural integrity of the AR in
individual breast tumour specimens, mean percentage areas
of positive staining for ARU402 and ARR489 in sequential
sections were compared (Figure 3). While AR immunostain-
ing in the majority of specimens was concordant between the
two antisera (P= 0.0001), a subset of ten tumours with mean
ARU402 staining of 20-38% exhibited mean ARR489 staining
of 48-72%, which deviated significantly from a linear
relationship. In addition, nine of the subset of ten tumours
with reduced ARU402 staining showed reduced staining with
10-38% positivity for ARU407, an AR antibody to internal
amino acids in the A domain of the receptor (data not
shown). The mean percentage area stained for ARU402 and for
ARU407 was concordant in all tumours evaluated (P<0.03).
The area of apo-D immunoreactivity in breast tumour













Figure 1 Immunostaining for ARU402 and apo-D in breast
tumours. Paraffin sections were stained for either ARU402 or apo-
D as described in the text. (a) A breast cancer containing strongly
AR-positive tumour cells. Stromal cells are negatively stained. (b)
A breast tumour with weak AR-positive staining. (c) Sequential
paraffin section from same breast tumour as b demonstrating apo-
D-positive and -negative foci of tumour cells. In this tumour apo-
D did not colocalise with AR and apo-D staining was evident in
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Figure 2 Video image analysis of AR immunostaining in breast
tumours. Correlation between the mean (±s.e.m.) percentage area
of positively stained cells and the mean concentration of antigen
expressed over the total population ofcancer cells (MIOD) for (a)
ARU402, AR amino-terminal antiserum (r=0.99, P=0.0001) and
(b) ARR489, AR carboxy-terminal antiserum (r= 0.89, P= 0.0001).
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Figure 3 Video image analysis comparison of ARU402 and
ARR489 immunostaining in breast tumours. Correlation between
the mean (±s.e.m.) percentage area of positively stained cells for
ARU402 and ARR489 for 20 (C1) breast tumours (r=0.815,
P=0.0001). Ten breast tumours (U) showed discordant staining
for ARU402 and ARR489 and were not included in linear
regression analysis.
Three of 31 evaluable tumour specimens were negative for
apo-D (i.e. <1% apo-D-positive cells). In accordance with
AR immunostaining, the percentage of apo-D-positive cells
was found to be significantly related to the MIOD for apo-D
staining in individual specimens (P=0.0001; Figure 4a). No
association between the mean percentage area of positively
stained cells for apo-D and the mean percentage area of
positively stained cells for ARU02 was observed in this cohort
of breast cancer specimens (Figure 4b). Similar results were
found when mean percentage positive area of apo-D and
ARR489 staining were compared or when MIOD of apo-D
staining was compared with either MIOD of ARU102 or
MIOD of ARR489 staining (data not shown).
Discussion
Although the role of the AR in breast tumorigenesis, growth
of breast cancers and tumour responsiveness to endocrine
therapies is poorly understood, the widespread expression of
AR demonstrated in the present and previous studies (Isola,
1993; Kuenen-Boumeester et al., 1992; Lea et al., 1989)
suggests that this pathway may be of biological and clinical
importance in human breast cancer. In this study, AR
immunoreactivity was evident in all of the breast tumours
evaluated. Two recent immunohistochemical studies reported
incidences of 76% (Kuenen-Boumeester et al., 1992) and 79%
AR-positive breast tumours (Isola, 1993). The lower levels of
AR expression reported in these studies may have been due
to decreased sensitivity ofthe monoclonal antibody employed
(F39.4) as compared with polyclonal antisera ARU402 and
ARR489, and the use in these studies of arbitrary cut-offs for
AR positivity of 10% (Kuenen-Boumeester et al., 1992) or
20% AR-positive cells (Isola, 1993). In addition, the use of
VIA in the present study has permitted analysis of a larger
proportion of the tumour specimen and more sensitive
detection of breast cancers expressing low levels of AR. Of
interest was the similar finding of the current study and that
of Kuenen-Boumeester et al. (1992), which reported that the
intensity of AR immunoreactivity in breast cancer cells was
directly proportional to the percentage of AR-positive nuclei.
These observations are in contrast to that seen in human
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Figure 4 Video image analysis of apo-D immunostaining in
breast tumours. (a) Correlation between the mean (±s.e.m.)
percentage area of positively stained cells and the mean
concentration of antigen expressed over the total population of
cancer cells (MIOD) for apo-D (r=0.99, P=0.0001). (b)
Comparison of the mean (±s.e.m.) percentage area of positively
stained cells for ARU402 and apo-D. No relationship between AR
and apo-D immunostaining was evident in individual breast
specimens.
results) and suggest altered regulation of AR expression and/
or stability in breast cancer.
AR immunoreactivity was localised to the nuclei of
tumour cells and no stromal staining was observed. Stromal
AR positivity has been reported in a single study in non-
malignant breast specimens (Kimura et al., 1993). However,
the studies of Kuenen-Boumeester et al. (1992) and Isola
(1993) report negative staining for AR in breast cancer-
associated stromal cells. While ER and PR are also localised
in the nucleus of malignant and non-malignant breast
epithelial cells and are not present in the stroma (Isola,
1993; Kuenen-Boumeester et al., 1992), AR, ER and PR are
detected in both epithelial and stromal cells of the prostate
(Brolin et al., 1992; Husmann et al., 1990). The functional
significances of the localisation of these receptors in relation
to the biological actions of the steroid ligands in breast and
prostate is unknown. However, since the AR, ER and PR are
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absent from breast stroma. paracrine factors are unlikely to
mediate steroid effects in breast cancer. as they do in the
prostate (Steiner. 1995).
We have previously demonstrated that differential staining
with antisera that bind to epitopes in the amino- and
carboxy-termini of the AR may be used to detect prostate
cancer specimens contaimng amino acid substitutions in the
AR (Tilley et al.. 1996). The finding of ten breast tumour
specimens with discordant staining between the amino- and
carboxy-termini of the AR is similarly suggestive of structural
alterations in the AR protein complex. Recently. a novel
87 kDa isoform of the AR was reported in human genital
skin fibroblasts (Wilson and McPhaul. 1994). The distnrbu-
tion of this AR isoform in other human tissues and its
functional activity have not yet been characterised. Decreased
AR immunostaining at the amino-terminus of the receptor in
individual breast tumour specimens may therefore also
indicate the presence of amino-terminal truncated variants
of AR. in addition to AR gene mutations that result in amino
acid substitutions. However. it is unlikely that the 87 kDa
isoform contributes to the discordance in immnunoreactivity at
the amino- and carboxy-termini of the AR in the present
study, since nine of these ten tumours also showed discordant
staining between AR antisera directed against an internal AR
epitope. which recognises the 87 kDa AR isoform and the
carboxy-terminal AR antisera. Further cDNA sequence
analysis of AR will confirm the presence of mutations and
or alternative AR isoforms in these breast cancer specimens.
Increased expression of apo-D in breast cancers has been
associated previously with longer relapse-free and overall
survival (Diez-Itza et al.. 1994). In that study. expression of
apo-D was not found to be related to ER or staining for the
oestrogen-responsive gene. pS2. Although apo-D regulation
by androgens is evident in breast cancer cell lines in vitro
(Haagensen et al.. 1992: Simard et al.. 1992). the lack of
correlation between AR and apo-D immunostaining in breast
cancer cells and tumour tissues in vivo suggests that factors
other than AR regulate cellular apo-D levels in breast
cancers. Whereas progestins. glucocorticoids. retinoids and
interleukin lx have been shown to regulate apo-D levels in
vitro (Blais et al.. 1994: Lambert et al.. 1993: Lopez-Boado et
al.. 1994). the association of such factors with cellular levels
of apo-D in breast tumour cells is unknown. These
determinants. or the presence of apo-D itself. however. may
confer the observed prognostic advantage to patients with
breast cancers expressing increased levels of apo-D.
The findings in the present study of a wide range of AR
immunopositivity in primary breast tumours and the previous
correlation of AR levels and response to hormonal (MPA)
therapy (Birrell et al.. 1995b) indicate that AR function is an
important mediator of breast cancer cell growth in viso.
Cellular apo-D does not appear to be related to AR levels in
the tumours examined and therefore is not useful as a marker
of AR function. However. quantitative immunohistochemical
analysis of AR suggests that structural alterations or
alternative isoforms of the receptor may be present in a
proportion of breast tumours. Characterisation of Wild type
or abnormal functional activitv of AR in breast tumour cells
will determine the contnrbution of AR to growth and
hormonal responsiveness of human breast cancers.
Abbreviations
AR. androgen receptor; apo-D. apolipoprotein D: DAB. 3'-3-
diaminobenzidine tetrahydrochloride: ER. oestrogen receptor:
IOD. integrated optical density: MIOD. mean integrated optical
density: MPA. medroxyprogesterone acetate: PR. progesterone
receptor: ARR489. anti-carboxv-terminal AR antibody: AR
anti-amino-terminal AR antibody: ARu4-f. antibody to the
internal A domain of AR; VIA. Video image analysis.
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